Biomedtracker and Datamonitor Healthcare present the post-report for the 67th Annual Meeting of the American Society of Hematology (ASH) held in San Diego, California from December 6-9, 2025. Conference highlights include:

• FLT3 inhibitor crenolanib demonstrates niche benefits at ASH 2025 in relapsed/refractory AML patients
• Komzifti continues to demonstrate competitive efficacy and safety with positive initial Phase I trial results
• Olverembatinib demonstrates impressive MRD-negativity rates in untreated Ph+ ALL, setting up FDA and EMA clearance

This post-meeting report features commentary from our analysts on specific presentations. It also includes a compilation of all data events added in conjunction with the meeting.